Lutein

Evidence Fact Sheet

Macular Xanthophyll · β,ε-Carotene-3,3′-diol

Educational reference page on lutein — the oxygen-containing carotenoid (xanthophyll) humans cannot synthesize, biochemical partner of zeaxanthin in the macular pigment. This page reports the AREDS2 trial honestly (the primary endpoint did not reach pre-specified statistical significance; only the lowest-baseline-intake quartile showed a 26% reduction), distinguishes AREDS1 from AREDS2 cleanly, locates the lutein-zeaxanthin combination correctly in the β-carotene smoker-safety history (ATBC 1994, CARET 1996), and walks through the four-jurisdiction regulatory matrix (US, EU, China, Brazil). This sub-page sits inside the carotenoids cluster hub alongside its sibling pages. Educational content. Not medical advice.

Last reviewed 2026-05-24 · How we assess evidence →

§1 · Quick Summary (60-second read)

Lutein is a xanthophyll carotenoid the body cannot make and must obtain from food — primarily dark leafy greens (kale, spinach, watercress) and egg yolks. Together with zeaxanthin, it is one of the only carotenoids the body actively concentrates in a specific tissue: the macula at the back of the retina, to roughly 1,000 times plasma concentration.

Three things to know before you read further:

AREDS2 (NIH/NEI · n=4,203 · 10 mg lutein + 2 mg zeaxanthin/d) is the centre of gravity of the lutein evidence base — and it must be read honestly. The primary AMD-progression endpoint across the full study population did not reach pre-specified statistical significance. In the pre-specified subgroup with the lowest baseline dietary L+Z intake, the combination produced a 26% relative reduction in progression (HR 0.74, 95% CI 0.59–0.94). The trial enrolled adults who already had intermediate AMD or advanced AMD in one eye — not healthy general-population adults — and the formulation is recommended for that already-at-risk population to slow progression, not as primary AMD prevention.
AREDS1 and AREDS2 are different formulas and must not be conflated. AREDS1 (1992–2001, NCT00000145) contained 15 mg β-carotene and no lutein. AREDS2 substituted L 10 mg + Z 2 mg for β-carotene specifically to remove the lung-cancer signal seen in heavy smokers in the ATBC (1994 · 18% lung-cancer increase) and CARET (1996 · 28% lung-cancer increase) trials. Lutein neither causes nor prevents lung cancer — it is simply a safer carotenoid choice for current and former smokers.
Macular pigment biophysically absorbs short-wavelength visible light near 445 nm — this is the optics fact, stateable. Several small RCTs in screen-exposed adults show 6–12 months of L+Z supplementation raises macular pigment optical density (MPOD), improves contrast sensitivity, photostress recovery and glare disability, and in some studies reduces self-reported visual fatigue. These are supportive evidence, not a treatment claim for digital eye strain or computer vision syndrome.

Bottom line: dietary lutein from leafy greens and eggs is well-characterized, well-tolerated, and reaches the macula via highly selective retinal transport (StARD3 for lutein, GSTP1 for zeaxanthin). For most adults the cheapest and best-evidenced intervention remains a daily salad. For adults with intermediate AMD or advanced AMD in one eye the AREDS2 formula is appropriate under ophthalmologic guidance. For the rest, supplements at 6–10 mg/d are a reasonable adjunct when dietary intake of greens is low, with an AREDS2-aligned ceiling of about 20 mg/d.

§2 · What lutein is — and why it is not the same as zeaxanthin or β-carotene

Lutein is a xanthophyll carotenoid humans cannot synthesize and must obtain from food — primarily dark leafy greens and egg yolks — that the body selectively concentrates in the macula to roughly 1,000 times plasma concentration.

Lutein is a xanthophyll carotenoid with the chemical name β,ε-carotene-3,3′-diol. Its 40-carbon backbone, built from eight isoprenoid units, ends in two different ring structures: one β-ionone and one ε-ionone (an arrangement that produces an allylic hydroxyl with a slightly different orientation). Each ring carries a single hydroxyl (-OH). This makes lutein a polar, oxygen-containing carotenoid that sits at the water-lipid interface of biological membranes rather than burying deep in the lipid core. Three distinctions explain almost every confusion in popular writing about lutein.

§2.1 · Lutein vs. zeaxanthin

Zeaxanthin (β,β-carotene-3,3′-diol) is a stereoisomer of lutein with two symmetric β-rings. Both carry the same two hydroxyls and absorb in the same blue-violet region, but the ring asymmetry changes how each one orients in membranes and how each is bound by retinal transport proteins (StARD3 for lutein, GSTP1 for zeaxanthin). Lutein dominates the peripheral macula and the Henle fibre layer; zeaxanthin and its meso-zeaxanthin (3R,3′S) diastereomer dominate the central fovea. This is why AREDS2 did not test lutein alone — it tested a 10 mg lutein + 2 mg zeaxanthin combination approximating the natural macular pigment composition. The two are partners, not substitutes. The zeaxanthin sub-page covers its own absorption profile, food sources and clinical evidence; do not extrapolate claims about one to the other.

§2.2 · Lutein vs. meso-zeaxanthin

Meso-zeaxanthin (3R,3′S) is not present in any significant amount in the ordinary diet — trace amounts occur in shrimp and crab shells but it is essentially absent from leafy greens, eggs or supplements unless specifically added. Instead, the body generates meso-zeaxanthin in the retina by enzymatically isomerizing lutein (a step thought to involve RPE65). Meso-zeaxanthin is not an independent essential nutrient; the reliable way to obtain it is adequate dietary lutein. Some advanced formulas add it directly, but the supplemental evidence base remains thinner than for the lutein-zeaxanthin pair.

§2.3 · Lutein vs. β-carotene

β-carotene is a carotene (no hydroxyls, two β-rings, no oxygen) and a provitamin A; the body can cleave it to vitamin A. Lutein cannot be converted to vitamin A and so does not carry the hypervitaminosis A risks of preformed retinol. It also did not produce the safety concerns seen in the two large randomized trials of high-dose β-carotene in heavy smokers (ATBC 1994, CARET 1996; see §7.2). The two compounds belong to the same chemical family but behave very differently in the body and in clinical trials.

§2.4 · The macular pigment — a thousand-fold concentration gradient

The macular pigment — the yellow spot at the back of the retina from which the macula lutea gets its name — comprises lutein, zeaxanthin and meso-zeaxanthin in a radial gradient: meso-zeaxanthin most concentrated in the central foveola, zeaxanthin dominant across the fovea, lutein dominant peripherally. The total L+Z concentration in macular tissue is roughly a thousand times higher than in blood plasma, making the macula one of the most striking examples of selective nutrient accumulation in human biology.

§3 · Food sources and dietary intake

Because humans cannot synthesize lutein, every microgram comes from food. The richest dietary sources fall into two categories: dark leafy greens (lutein-dominant) and yellow-orange foods such as corn, egg yolk and red pepper (mixed L+Z, often zeaxanthin-leaning).

Food	Lutein + zeaxanthin (mg / 100 g edible)	Notes
Kale, raw	18–39	Highest among common foods; varies by cultivar
Spinach, raw	≈ 12.2	A 30 g cup delivers roughly 3.7 mg
Watercress, raw	≈ 5.8	Often overlooked but very rich
Egg yolk (1 large, ≈ 17 g)	0.25–0.36 per yolk	Bioavailability is unusually high because lutein is delivered in a natural lipid-protein matrix
Peas, cooked	≈ 2.5
Corn, cooked	≈ 0.9	Predominantly zeaxanthin
Sweet red pepper	≈ 0.5	Predominantly zeaxanthin
Goji berries, dried	5–10	A notable zeaxanthin source in East Asian cuisine
Marigold petals (Tagetes erecta), dried	≥ 1,000	Commercial extraction source; not a food

Two real-world intake facts are worth holding side by side. First, the average U.S. adult consumes only about 1–2 mg of L+Z per day (NHANES). Second, AREDS2 used 12 mg/day combined (10 mg lutein + 2 mg zeaxanthin) — roughly six to twelve times typical intake. This gap is the empirical basis for both dietary advice ("eat more leafy greens") and the supplement category. There is no RDA for lutein in the United States; the Institute of Medicine has not set one because lutein is not classified as an essential vitamin and no deficiency syndrome has been defined. Practically, a daily serving of cooked spinach, a handful of kale, or one to two whole eggs contributes meaningfully. Because lutein is fat-soluble, pairing greens with olive oil, avocado, nuts or egg yolk improves absorption substantially (see §4).

§4 · Absorption, transport, and selective deposition in the macula

Lutein is transported to the retina by StARD3 protein and selectively accumulates in the macula as macular pigment alongside zeaxanthin and meso-zeaxanthin, where it absorbs short-wavelength visible light peaking near 445 nm and acts as an optical filter for blue-violet light.

Lutein behaves like other fat-soluble nutrients in the digestive tract: it must be liberated from the food matrix, packaged with dietary fat, taken up by intestinal cells, and shipped through the lymphatic and circulatory systems before reaching the retina. What makes lutein distinctive is what happens at the destination.

§4.1 · Intestinal absorption — and a controlled β-carotene competition

In the small intestine, lutein is incorporated into bile-acid micelles with dietary fat, taken up across the enterocyte brush border (SR-BI plays a major role), packaged into chylomicrons, and released into the lymphatic circulation. Absorption efficiency is modest — approximately 5–29% depending on individual factors, food matrix and co-consumed nutrients. Egg yolk delivers lutein with particularly high bioavailability (natural phospholipids and lipoproteins act as built-in absorption enhancers); spinach delivers less per milligram unless leaves are well chewed or cooked with oil; tablets and powders without an oil carrier sit at the lower end.

A specific competition matters at the supplement level. A controlled crossover PK study by Kostic and colleagues (1995) in 11 adults showed that co-administration of high-dose β-carotene reduced lutein absorption by roughly 39–46% (remaining lutein appearance corresponded to about 54–61% of the lutein-alone control) [PMID 7661123]. The reverse was also observed. Combination carotenoid products with high β-carotene doses, or simultaneously taken single-carotenoid supplements, can interfere with each other; spacing them across meals or choosing a single lutein-zeaxanthin product avoids the issue.

§4.2 · Free-form vs. ester forms

Free-form lutein (used in AREDS2) has exposed terminal hydroxyls and is ready for chylomicron incorporation. Lutein esters are bound to long-chain fatty acids and must be hydrolysed by intestinal carboxyl-ester lipase before absorption. Free-form is slightly more bioavailable per milligram in some PK studies; the difference narrows when esters are taken with a fat-containing meal. Labels should specify which form is provided and whether the milligram figure refers to free lutein equivalent.

§4.3 · Circulation and storage — HDL preference

After absorption, lutein moves via chylomicrons to the liver and is redistributed in VLDL, LDL and HDL. Unlike β-carotene (predominantly LDL), lutein and zeaxanthin show a notable preference for HDL — roughly half of plasma lutein is carried in HDL particles. Plasma half-life is approximately 5–7 days; supplementation reaches steady state in about 4–6 weeks and returns to baseline 6–8 weeks after stopping.

§4.4 · Selective uptake by the macula — StARD3 and GSTP1

Two retinal proteins act as molecular tweezers, plucking specific carotenoids from circulation: StARD3 binds lutein with high specificity, and GSTP1 binds zeaxanthin. These transporters explain the radial pigment gradient described in §2.4 and why the macula accumulates L+Z to roughly a thousand times plasma concentration while largely excluding other circulating carotenoids. This deposition is measured non-invasively as macular pigment optical density (MPOD) by heterochromatic flicker photometry, autofluorescence imaging or resonance Raman spectroscopy [Leung 2008, PMID 18436167]. MPOD is the most important objective endpoint in clinical lutein research because it reflects how much lutein actually reaches the eye.

§5 · AREDS2 and the macular-pigment evidence base — read honestly

The clinical centre of gravity for lutein is the Age-Related Eye Disease Study 2 (AREDS2) — a multi-centre, double-blind, placebo-controlled trial run by the U.S. National Eye Institute (NIH/NEI). It is the single largest, longest, most rigorously designed evaluation of a lutein-containing nutrient combination ever conducted, and the way it is reported in marketing rarely matches the way the trial investigators reported it. Honest reading of AREDS2 is the most important thing this page can offer.

§5.1 · What AREDS2 tested — and how it differs from AREDS1

AREDS2 enrolled 4,203 adults aged 50–85 who already had a recognized risk profile for advanced AMD — either bilateral large drusen or large drusen in one eye with advanced AMD in the fellow eye [PMID 23644932; ClinicalTrials.gov NCT00345176]. They were not healthy general-population adults. The 2×2 factorial design randomized participants to L+Z (or not) and to omega-3 (DHA+EPA, or not), on top of a modified background AREDS formulation. The doses were 10 mg/day of free-form lutein extracted from marigold (Tagetes erecta) flowers + 2 mg/day of zeaxanthin, alongside vitamin C 500 mg, vitamin E 400 IU, zinc 25–80 mg, copper 2 mg. Median follow-up was ~5 years; a 10-year extension was reported in 2022 [PMID 35653117].

AREDS2 must be distinguished from the earlier AREDS1 trial (1992–2001, NCT00000145), which used a formula containing 15 mg/day of β-carotene and did not contain lutein or zeaxanthin. AREDS2 was designed specifically to test whether L+Z could replace β-carotene, motivated by the lung-cancer findings in heavy smokers from ATBC (1994) and CARET (1996) that made β-carotene supplementation unsafe in that population. Writing "AREDS showed lutein reduces AMD progression" without specifying which generation will mislead; the original AREDS1 had no lutein arm at all.

§5.2 · What AREDS2 actually found

RCT supported (primary full-population endpoint did not reach significance; subgroup significant)

Lutein and zeaxanthin reduced relative progression risk by 26% in adults with lowest baseline dietary intake, but the full-population primary endpoint did not reach pre-specified statistical significance.

26% reductionrelative risk reduction (lowest intake quartile)
n=4,203adults aged 50-85
10 mg L + 2 mg Z/daydoses over median ~5 years

Endpoint	Main 5-year result	10-year extension (2022)
Progression to advanced AMD (primary, full ITT)	~10% relative risk reduction with L+Z; did not reach pre-specified statistical significance	Long-term benefit signals persisted
Subgroup: lowest baseline dietary L+Z intake quartile	26% reduction in progression risk (HR 0.74, 95% CI 0.59–0.94, p < 0.05)	Benefit persisted in this subgroup
Safety in smokers (L+Z substituted for β-carotene)	No lung-cancer signal; β-carotene problem not reproduced	5- and 10-year safety reassuring; no L+Z serious AEs

The honest summary

Lutein and zeaxanthin did not show a statistically significant benefit on the primary AMD-progression endpoint across the full study population, but in the pre-specified subgroup with the lowest baseline dietary intake, the combination reduced relative progression risk by 26% [AREDS2 Report No. 3, PMID 24310343]. The trial's other major contribution was demonstrating that swapping L+Z for β-carotene produced a safe alternative formulation that was no less effective on AMD progression and could be recommended to current and former smokers.

The current NIH/NEI, NIH ODS and major ophthalmology consensus is that the AREDS2 formulation is appropriate as a nutritional intervention in people who already have intermediate AMD or advanced AMD in one eye, where the goal is to slow further progression. It is not recommended as a general AMD-prevention regimen in healthy adults with no signs of AMD and no strong family history. No published evidence supports long-term high-dose lutein supplementation as primary AMD prevention in lower-risk populations, and the trial was not designed to answer that question.

§5.3 · Supportive randomized trials (MPOD and visual performance)

RCT supported

Smaller randomized trials demonstrate that 6-12 months of lutein-zeaxanthin supplementation reliably increases macular pigment optical density and improves contrast sensitivity, photostress recovery, and in some studies reduces self-reported visual fatigue.

20 RCTsmeta-analysis dose-response
MPOD increased significantlyLUNA trial (6 months)
contrast sensitivity, eye-fatigue improvedMa et al. 2009 computer users study

Beyond AREDS2, smaller randomized trials and one meta-analysis have characterized how lutein supplementation affects macular pigment density and visual performance in adults without advanced eye disease.

LUNA (Trieschmann et al., 2007) — 108 healthy adults, lutein 12 mg + zeaxanthin 1 mg/day for 6 months. MPOD increased significantly; serum and MPOD change correlated linearly [PMID 17306793].
Ma et al., 2009 — 37 long-term computer users (China), lutein 6 or 12 mg/day for 12 weeks. The 12 mg group showed significant gains in contrast sensitivity, eye-fatigue scores and MPOD [PMID 19586568].
Hammond et al., 2014 (photostress recovery) — 115 healthy adults, lutein 10 mg + zeaxanthin 2 mg/day for 12 months. Photostress recovery and glare disability improved; chromatic contrast was enhanced [PMID 25468896].
Stringham et al., 2017 (screen exposure and sleep) — 48 high-screen-time adults, lutein 10 mg + zeaxanthin 2 mg + meso-zeaxanthin 10 mg/day for 6 months. Self-reported visual fatigue, headache and eye discomfort decreased; sleep-quality measures improved [PMID 28661438].
Ma et al., 2016 (meta-analysis) — 20 randomized trials demonstrating a consistent dose-response between supplemental L+Z and MPOD change, with effects typically detectable from 6 months [PMID 27420092].
Eisenhauer et al., 2017 (narrative review) — Overview of food sources, bioavailability and the lutein-zeaxanthin-AMD evidence base [PMID 28208784].

These trials support the conclusion that L+Z supplementation around AREDS2 doses reliably increases macular pigment density and improves several objective visual-performance endpoints in healthy adults. They do not establish that supplementation prevents age-related macular degeneration in the general population.

§6 · Blue light, screen exposure and digital eye strain — fact versus overreach

This is the section of the lutein literature where consumer marketing diverges most sharply from clinical evidence. The discussion below takes the conservative, NIH-aligned reading and walks through it in three explicit tiers.

§6.1 · Tier 1 — the biophysical fact

The macular pigment composed of lutein, zeaxanthin and meso-zeaxanthin absorbs short-wavelength visible light, peaking around 445 nm in the blue-violet portion of the visible spectrum. This has been documented in human and primate macular tissue since at least the 1980s and is uncontroversial. In a person with denser macular pigment, more of the incoming short-wavelength light is absorbed before reaching the photoreceptors and retinal pigment epithelium beneath. Macular pigment is the eye's own built-in optical filter for blue-violet light.

§6.2 · Tier 2 — what randomized trials show

RCT supported (supportive, not treatment claim)

Randomized trials in screen-exposed adults show that lutein-zeaxanthin supplementation raises macular pigment density and improves objective visual-performance markers and in some cases self-reported visual fatigue, supporting educational claims about screen exposure comfort.

visual fatigue, headache decreasedStringham 2017 high-screen-time
photostress recovery improvedHammond 2014 chromatic contrast
445 nm peak absorbancemacular pigment blue-violet light filter

Several small randomized trials in screen-exposed adults have measured what happens with 6–12 months of lutein-zeaxanthin supplementation. The pattern is reasonably consistent: MPOD rises, several objective visual-performance markers improve (contrast sensitivity, photostress recovery, glare disability), and in two trials (Ma 2009; Stringham 2017) self-reported visual fatigue decreased. These are real findings and the legitimate basis for cautious educational claims about lutein, screen exposure and visual comfort.

§6.3 · Tier 3 — what randomized trials do not show

They do not show that lutein "treats" digital eye strain or computer vision syndrome — both of which are clinical syndromes with multiple contributing causes including accommodative strain, reduced blink rate, dry eye, screen glare, and uncorrected refractive error. They do not show that supplementation prevents any specific eye disease caused by display use. The supporting trials were generally small (most enrolled fewer than 120 participants), single-centre, and not yet independently replicated at large scale.

The honest reading: macular pigment naturally filters short-wavelength visible light, and randomized studies in adults with high screen exposure suggest that 6–12 months of lutein and zeaxanthin supplementation can raise macular pigment density and improve some objective and subjective measures of visual comfort. This is supportive evidence, not a treatment claim. For people whose eyes feel tired after long screen sessions, the evidence-based first response is the unglamorous one: the 20-20-20 rule, well-positioned displays, appropriate ambient lighting, adequate blink rate, lubricating drops where dry eye is a factor, and a corrected refractive prescription. Lutein-rich foods or supplements can be a reasonable adjunct, particularly when dietary intake of greens is low, but they are not a substitute for ergonomic and ocular-surface care.

§7 · Cognition and skin photo-protection — bounded reads

Two other research directions have generated enough randomized data to mention briefly, with their boundaries clearly stated.

§7.1 · Cognition in older adults — CARES and centenarian autopsy

RCT supported (bounded)

The CARES trial in 62 older adults showed significant improvements in complex attention, cognitive flexibility and verbal fluency over 12 months of lutein-zeaxanthin supplementation, with improvement correlating to macular pigment rise.

n=62community-dwelling older adults
complex attention, cognitive flexibility, verbal fluency improvedendpoints
improvement correlated with MPOD risemechanistic link

The CARES trial (Hammond et al., 2017) randomized 62 community-dwelling older adults to 12 months of lutein 10 mg + zeaxanthin 2 mg/day. The supplement arm showed significant improvements in complex attention, cognitive flexibility and verbal fluency, and improvement correlated with the rise in macular pigment optical density [PMID 28824416]. An autopsy study by Johnson and colleagues (2013) in 30 individuals over the age of 100 found that brain-tissue concentrations of lutein and zeaxanthin correlated with cognitive scores during life [PMID 23840953]. CARES was a single-centre trial with 62 participants and used cognitive batteries as its endpoint, not clinical diagnoses. Nothing in the published literature supports a claim that lutein prevents, treats or reverses Alzheimer's disease or any form of dementia. The honest reading is that lutein reaches the brain, brain levels track with diet, and supplementation in older adults may improve some objective cognitive measures.

§7.2 · Skin and photo-protection — adjunct, not sunscreen replacement

RCT supported (adjunct, not sunscreen replacement)

Randomized trials in healthy adults show combined oral and topical lutein-zeaxanthin improves skin hydration, elasticity, and photo-protective markers, with improvements in skin tone and uniformity; however, this is adjunctive to, not a replacement for, topical sunscreen.

n=50 (Palombo), n=46 (Juturu)healthy adults and women
hydration, elasticity, surface lipid improvedPalombo 2007 outcomes
SPF 30+, shade, protective clothing remain dominantsunscreen necessity

Several randomized trials have tested oral lutein (sometimes combined with topical formulations) on skin parameters. Palombo et al. (2007), in 50 healthy adults over 12 weeks, found that combined oral + topical lutein/zeaxanthin produced consistent improvements in hydration, elasticity, surface lipid content and photo-protective activity markers [PMID 17446716]. Juturu et al. (2016) reported improvements in skin tone, brightness and uniformity in 46 women on lutein 10 mg + zeaxanthin 2 mg/day for 12 weeks [PMID 27785083]; Roberts and colleagues (2009) summarized the mechanistic background and clinical evidence [PMID 19168000]. The boundary is consistent with the FDA and major dermatology bodies: oral antioxidants, including lutein, do not replace broad-spectrum topical sunscreen. The dominant evidence-based protection against UV damage remains regularly applied SPF 30 or higher sunscreen, shade, and protective clothing.

§8 · Safety, tolerability and the smoker question

§8.1 · The safety profile in plain terms

Lutein is among the better-characterized dietary carotenoids for long-term safety.

Indicator	Value or conclusion	Source
Rodent no-observed-adverse-effect level (NOAEL, 52-week study)	≥ 400 mg/kg body weight/day	Crystalline lutein GRAS dossier, GRN 000140 (Kemin GRAS notifier, 2004)
European Food Safety Authority acceptable daily intake (ADI)	1 mg/kg body weight/day (approximately 70 mg/day for a 70 kg adult)	EFSA 2006 safety assessment
Joint FAO/WHO Expert Committee on Food Additives	No upper limit established; safety data considered adequate	JECFA 2006
Long-term human tolerance	AREDS2: 10 mg lutein + 2 mg zeaxanthin/day for 5+ years; no serious adverse events attributable to lutein/zeaxanthin	PMID 23644932; PMID 35653117
Cumulative clinical safety database	50+ human randomized trials, thousands of participants; no serious adverse events specifically attributed to lutein	Multiple
Most commonly reported side effect	Rare; sustained intake above approximately 30 mg/day can produce carotenodermia, a harmless, reversible yellowing of the skin that resolves on dose reduction	Cross-study consensus
Notable interactions	Orlistat and other fat-blocking agents reduce absorption; high-dose β-carotene competes for absorption (Kostic 1995, PMID 7661123); no signal for interaction with warfarin or other vitamin-K antagonists at typical supplement doses	—

At doses in the 10–20 mg/day range used in mainstream supplements and the AREDS2 protocol, the safety profile is reassuring and side-effect reports are uncommon. The most distinctive adverse effect, carotenodermia, is cosmetic rather than medical: when sustained intake from food plus supplements exceeds ~30 mg/day, lutein accumulates in subcutaneous fat enough to give skin a faint yellow-orange tint (most visible on palms and soles). It resolves within weeks of reducing intake.

Special-population data are limited. No randomized trials have evaluated supplement-level lutein in pregnant or breastfeeding women, or in children under 18. Food-source lutein is regarded as safe across the lifespan, and U.S. infant formulas may include lutein at limited levels under GRN 000221 (see §9). The conservative NIH ODS position is that these groups should obtain lutein from food unless a healthcare provider specifically recommends a supplement.

§8.2 · The β-carotene history — and why it matters for lutein

The reason lutein occupies its current position in mainstream eye-health recommendations is largely a story about β-carotene.

Two large 1990s randomized trials tested high-dose β-carotene in populations at elevated lung-cancer risk. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study randomized 29,133 male Finnish smokers to β-carotene 20 mg/day, vitamin E 50 mg/day, both, or placebo; after 5–8 years, β-carotene was associated with an 18% relative increase in lung-cancer incidence (RR 1.18, 95% CI 1.03–1.36) and a small all-cause mortality increase [PMID 8127329]. The β-Carotene and Retinol Efficacy Trial (CARET) (Omenn et al., 1996) randomized 18,314 smokers and asbestos-exposed adults to β-carotene 30 mg/day + retinol 25,000 IU/day or placebo; the trial was terminated ~21 months early when interim analyses showed a 28% relative increase in lung-cancer incidence (RR 1.28, 95% CI 1.04–1.57) and a 26% increase in cardiovascular death [PMID 8602180].

These results made β-carotene supplementation unacceptable in the original AREDS1 formula for anyone with a smoking history. The motivation for AREDS2 was largely to identify a replacement carotenoid without that signal, and lutein plus zeaxanthin was the leading candidate. In AREDS2's ~600 current and former smokers, L+Z produced no lung-cancer signal over five-year and ten-year follow-up.

§9 · Global regulatory status (United States · European Union · China · Brazil)

Lutein occupies different positions in different regulatory systems, and the differences matter for what manufacturers and platforms can lawfully say in each market.

Aspect	United States (FDA)	European Union (EFSA)	China (NMPA)	Brazil (ANVISA)
Regulatory identity	GRAS Notice GRN 000140 for crystalline lutein, general food use (notified 2004); GRN 000221 for use in term infant formula at limits up to 250 µg/L (2007). Dietary supplements regulated under DSHEA with permitted structure/function claims.	Authorized as a food supplement ingredient under the Food Supplement Directive 2002/46/EC.	Permitted as a nutritional fortifier under GB 14880, and as a registered health food functional ingredient ("lutein esters") for the specific functional claim "alleviation of visual fatigue" under the filing system.	Permitted on the positive list of carotenoids under RDC 243/2018.
Food and supplement use	Permitted	Permitted	Permitted	Permitted
Independent macular or vision health claim	Permitted as a structure/function claim with mandatory FDA disclaimer; an authorized qualified health claim for AMD has not been issued.	EFSA rejected multiple Article 13.1 and Article 14 applications in 2012 for claims relating to maintenance of normal vision, support of macular health, and blue-light filtration. Only general "contributes to the protection of cells from oxidative stress" claims are available via co-formulation with authorized antioxidant vitamins (vitamin C, vitamin E).	Permitted "alleviation of visual fatigue" claim for registered health foods only — not for ordinary foods or cross-border e-commerce products.	General visual-health claims permitted; disease-risk-reduction claims are not.
Fermentation or microalgae source	Requires independent GRAS notification.	Subject to Novel Food Regulation (EU) 2015/2283 authorization.	Requires new-food-ingredient filing (typical 2–3 year process).	Additional safety dossier required.
Typical commercial dose range	10–40 mg/day	Up to approximately 70 mg/day (anchored to ADI)	Per registered health food specification	6–20 mg/day
Mandatory disclaimer (US structure/function)	"This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease."	—	—	—

Three regulatory points commonly catch readers off-guard.

The European Union has the strictest position on independent health claims for lutein. In 2012 EFSA issued negative opinions on multiple Article 13.1 and Article 14 applications relating to macular health, vision maintenance and blue-light filtration, on the basis that submitted evidence did not establish the required cause-and-effect relationship at the population level. Consequently, lutein supplements sold in the EU cannot lawfully carry independent macular, vision or blue-light claims; antioxidant-related communication must rely on co-formulation with an authorized vitamin (C or E).
China permits a single specific claim — "alleviation of visual fatigue" — and only for properly registered health foods using lutein esters. Ordinary foods and the large cross-border e-commerce category cannot use this claim.
The United States is the most permissive of the four jurisdictions for educational and structure/function language, but still prohibits any claim that a lutein product "treats," "prevents," "cures" or "reduces the risk of" AMD or any other disease, and any structure/function statement must carry the standard FDA disclaimer.

The same lutein product cannot communicate identical claims in every country; the strictest market (the EU) should generally set the ceiling for marketing copy. Editorial pages such as this one are educational and do not constitute health claims about specific products.

§10 · Choosing a lutein supplement — when and how

General adult starting range 6-10 mg/day lutein; AREDS2 protocol 10 mg lutein + 2 mg zeaxanthin/day for adults with intermediate or advanced AMD; AREDS2-aligned ceiling approximately 20 mg/day; EFSA acceptable daily intake 1 mg/kg body weight/day (approximately 70 mg/day for a 70 kg adult).

Once a person has decided, in consultation with a healthcare provider where appropriate, that a lutein supplement makes sense, five practical questions cover most of the decision.

Form. Free-form lutein (the form used in AREDS2, extracted from marigold flowers and saponified to expose the terminal hydroxyls) has slightly higher per-milligram bioavailability than lutein esters, which must be hydrolysed by intestinal carboxyl-ester lipase before absorption. The label should state which form is provided and whether the milligram figure refers to free lutein equivalent or to ester weight.
Pairing with zeaxanthin. The macular pigment is composed of lutein and zeaxanthin in an approximately 5:1 ratio, and the AREDS2 trial used 10 mg lutein + 2 mg zeaxanthin. Products matching that ratio most closely approximate both natural dietary patterns and the formulation with the strongest clinical evidence. Some products also include meso-zeaxanthin (typically around 10 mg), but as noted in §2.2, meso-zeaxanthin is not an independent essential nutrient — the body generates it from lutein in the retina, and the supplemental form's incremental clinical value remains less well established than the lutein-zeaxanthin pair.
Delivery and timing. Oil-based softgels generally outperform tablets, powders and gummies because lutein is fat-soluble and benefits from a lipid carrier. Take with a meal containing at least about 5 grams of fat (olive oil, avocado, nuts, eggs or fatty fish); empty-stomach or strictly low-fat administration significantly reduces absorption.
Carotenoid interactions. Avoid taking a separate high-dose β-carotene supplement at the same time as lutein; the two compete for intestinal absorption, with co-administration of high-dose β-carotene reducing lutein bioavailability by roughly 39–46% in controlled studies (PMID 7661123). Space them across different meals if both are wanted.
Dose ranges. A reasonable starting range for adults is 6–10 mg/day, and the AREDS2-aligned upper level for most users is 20 mg/day. Doses substantially above this range are not better-supported and may produce visible carotenodermia at long duration. Adults with consistently strong intake of leafy greens may not need a supplement at all; the cheapest and best-evidenced lutein intervention remains a daily salad.

Cluster Sibling Sub-pages

This sub-page sits inside the carotenoids cluster hub. Lutein's most important sibling is its macular pair partner zeaxanthin; the other four siblings clarify what is and is not specific to lutein within the broader carotenoid family.

Zeaxanthin — Macular pair partner · β,β-carotene-3,3′-diol stereoisomer · GSTP1 transport vs StARD3 · dominates central fovea while lutein dominates peripheral macula · AREDS2 10:2 ratio (L:Z) reflects natural macular pigment composition
Carotenoids hub — Parent overview for the 600+ pigment family · shared mechanisms (conjugated polyene singlet-oxygen quenching · lipid peroxidation interruption · fat-soluble absorption · no human biosynthesis)
Astaxanthin — Sibling xanthophyll · crosses blood-retinal barrier to photoreceptor inner/outer segment junction (different retinal compartment than lutein-rich Henle fibre layer) · independent eye-fatigue evidence base · complementary, not interchangeable
β-carotene — The carotene the AREDS2 formula replaced · ATBC (1994 · 18% lung-cancer increase in male smokers at 20 mg/d) and CARET (1996 · 28% lung-cancer increase in smokers + asbestos-exposed at 30 mg/d) drove the L+Z substitution · lutein neither causes nor prevents lung cancer
Fucoxanthin — Sibling xanthophyll from brown algae · distinct allene structure · clinical-evidence base focuses on metabolic and adipose endpoints rather than the eye

§12 · References

All 18 lutein-specific PMIDs cited on this page were verified against PubMed (2026-05-24). Effect sizes are reported as published. The two β-carotene smoker-safety trials (ATBC 1994 · CARET 1996) are cited as part of the AREDS1→AREDS2 historical context, not as lutein trials.

Lutein-specific PMIDs cited on this page (18)

PMID 23644932 · AREDS2 Research Group 2013 · "Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration" · JAMA 309(19):2005–2015 · n=4,203 · 10 mg L + 2 mg Z/d · primary endpoint NS across full ITT
PMID 24310343 · AREDS2 Research Group 2014 · "Secondary analyses of the effects of lutein/zeaxanthin on AMD progression: AREDS2 Report No. 3" · JAMA Ophthalmology 132(2):142–149 · subgroup with lowest baseline dietary L+Z intake: HR 0.74 (95% CI 0.59–0.94, p < 0.05) · 26% relative reduction
PMID 35653117 · Chew EY et al. 2022 · "Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on AMD progression: AREDS2 Report 28" · JAMA Ophthalmology 140(7):692–698 · 10-year extension · long-term benefit signals persisted; safety reassuring
PMID 27420092 · Ma L et al. 2016 · meta-analysis · 20 RCTs · dose-response between supplemental L+Z and MPOD change · effects typically detectable from 6 months
PMID 28208784 · Eisenhauer B, Natoli S, Liew G, Flood VM 2017 · narrative review · food sources, bioavailability and L+Z–AMD evidence base
PMID 28661438 · Stringham JM et al. 2017 · n=48 high-screen-time adults · L 10 mg + Z 2 mg + meso-Z 10 mg/d × 6 mo · visual fatigue, headache, eye discomfort decreased; sleep quality improved
PMID 19586568 · Ma L et al. 2009 · n=37 long-term computer users (China) · lutein 6 or 12 mg/d × 12 wk · 12 mg group: contrast sensitivity, eye-fatigue scores, MPOD significantly improved
PMID 25468896 · Hammond BR Jr et al. 2014 · n=115 healthy adults · L 10 mg + Z 2 mg/d × 12 mo · photostress recovery, glare disability, chromatic contrast improved
PMID 28824416 · Hammond BR Jr et al. (CARES) 2017 · n=62 community-dwelling older adults · L 10 mg + Z 2 mg/d × 12 mo · improvements in complex attention, cognitive flexibility, verbal fluency correlated with MPOD rise
PMID 23840953 · Johnson EJ et al. 2013 · autopsy study · 30 individuals over age 100 · brain-tissue L and Z correlated with antemortem cognitive scores
PMID 17446716 · Palombo P et al. 2007 · n=50 healthy adults × 12 wk · combined oral + topical L/Z · improvements in hydration, elasticity, surface lipid content, photo-protective activity markers
PMID 27785083 · Juturu V, Bowman JP, Deshpande J 2016 · n=46 women · L 10 mg + Z 2 mg/d × 12 wk · improvements in skin tone, brightness, uniformity
PMID 19168000 · Roberts RL, Green J, Lewis B 2009 · review · mechanistic background and clinical evidence for L and Z in eye and skin health
PMID 17306793 · Trieschmann M et al. (LUNA) 2007 · n=108 healthy adults · L 12 mg + Z 1 mg/d × 6 mo · MPOD increased significantly; serum and MPOD change correlated linearly
PMID 18436167 · Leung IY 2008 · review · macular pigment and its constituents — measurement (heterochromatic flicker photometry, autofluorescence, resonance Raman) and clinical significance
PMID 7661123 · Kostic D, White WS, Olson JA 1995 · n=11 controlled crossover PK · high-dose β-carotene reduced lutein absorption by 39–46% (remaining lutein appearance ~54–61% of lutein-alone control); reverse also observed
PMID 8602180 · Omenn GS et al. (CARET) 1996 · n=18,314 smokers + asbestos-exposed · β-carotene 30 mg/d + retinol 25,000 IU/d · trial terminated ~21 mo early · 28% relative increase in lung-cancer incidence (RR 1.28, 95% CI 1.04–1.57) · cited for AREDS1→AREDS2 substitution rationale
PMID 8127329 · ATBC Study Group 1994 · n=29,133 male Finnish smokers · β-carotene 20 mg/d · 18% relative increase in lung-cancer incidence (RR 1.18, 95% CI 1.03–1.36) · cited for AREDS1→AREDS2 substitution rationale

Regulatory and Public-Health References (not counted in PMID total)

FDA GRN 000140 (2004) · GRAS Notice for crystalline lutein, general food use · Kemin GRAS notifier · referenced as factual NIH-ODS practice citation only (no brand mention)
FDA GRN 000221 (2007) · GRAS Notice for use in term infant formula at limits up to 250 µg/L
EFSA 2006 · safety assessment establishing acceptable daily intake (ADI) of 1 mg/kg body weight/day for lutein
EFSA 2012 · negative opinions on multiple Article 13.1 and Article 14 applications relating to macular health, vision maintenance and blue-light filtration claims for lutein
JECFA 2006 · Joint FAO/WHO Expert Committee on Food Additives · no upper limit established for lutein
China GB 14880 · nutritional fortifier permission for lutein; registered health food filing system permits "alleviation of visual fatigue" claim for lutein esters under specific filing only
ANVISA RDC 243/2018 · Brazil positive list of carotenoids · permits lutein as food and supplement ingredient
NIH Office of Dietary Supplements · current consumer-facing reference recommending AREDS2 formulation in already-at-risk AMD populations, not as primary prevention in healthy adults
U.S. National Eye Institute (NEI) · clinical guidance aligned with AREDS2 published results; not endorsed as general AMD prevention in healthy adults
Linus Pauling Institute Micronutrient Information Center · Lutein and Zeaxanthin · educational reference aligned with the AREDS2 honest reading
NHANES · average U.S. adult L+Z intake 1–2 mg/day

Educational Disclaimer

Educational content. Not medical advice. Consult a qualified healthcare provider before starting any supplement, particularly if you have an existing medical condition, are pregnant or breastfeeding, take prescription medications, or are an active or former heavy smoker. This page does not diagnose, treat, cure, or prevent any disease. FDA structure/function statement: any structure/function statement about lutein in U.S. dietary supplement labeling must carry the standard disclaimer — "This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease." Brand and product names are not endorsed; the criteria described are evidence-based generic standards (free-form vs. ester disclosure, transparent L:Z ratio labeling, oil-based delivery, AREDS2-aligned dosing) that any compliant product can meet.

§11 · Frequently Asked Questions

The questions below are the most-searched questions on lutein across general web search and AI assistants. Answers reflect the evidence cited throughout this page and are intentionally concise; deeper detail lives in the relevant sections above.

1. Is lutein safe to take every day?

Yes, for most adults. Daily intake at the 10–20 mg level used in mainstream supplements and AREDS2 has a strong safety record across more than fifty randomized trials, and EFSA sets an acceptable daily intake of 1 mg/kg body weight (about 70 mg/day for a 70 kg adult). Sustained intake above ~30 mg/day can produce a harmless, reversible yellowing of the skin (carotenodermia). Pregnant or breastfeeding women and children under 18 should obtain lutein from food unless a healthcare provider specifically recommends a supplement.

2. What is the difference between lutein and zeaxanthin?

Both are xanthophyll carotenoids with the same molecular formula and two hydroxyls, but lutein has one β-ring and one ε-ring while zeaxanthin has two symmetric β-rings. Lutein predominates in the peripheral macula and Henle fibre layer; zeaxanthin in the central fovea. AREDS2 used a 10:2 ratio (lutein : zeaxanthin), reflecting natural dietary patterns. The two are partners, not interchangeable. See the dedicated zeaxanthin sub-page.

3. Does lutein prevent age-related macular degeneration?

The AREDS2 trial tested lutein and zeaxanthin in adults who already had intermediate AMD or advanced AMD in one eye. In that population the combination reduced relative progression risk by approximately 26% in the subgroup with the lowest baseline dietary intake; the primary endpoint across the full study did not reach pre-specified statistical significance. No randomized evidence shows that lutein supplementation prevents AMD from developing in healthy adults without risk factors. NIH ODS and NEI recommend the AREDS2 formula for the at-risk population studied in the trial, not as general prevention.

4. Does lutein help with digital eye strain?

Small randomized trials suggest that 6–12 months of lutein and zeaxanthin supplementation can raise macular pigment optical density, improve contrast sensitivity and photostress recovery, and in some studies reduce self-reported visual fatigue in high-screen-time adults. These are supportive findings, not a treatment claim for digital eye strain or computer vision syndrome, which are clinical conditions with multiple causes that require comprehensive ergonomic and ocular-surface management (20-20-20 rule, proper lighting, corrected refraction, dry-eye care).

5. Is lutein safer than β-carotene for smokers?

Lutein does not carry the lung-cancer signal seen with high-dose β-carotene in heavy smokers (ATBC 1994 and CARET 1996), and lutein was specifically substituted for β-carotene in the AREDS2 formula to remove that concern. Lutein neither causes nor prevents lung cancer; it is simply a safer carotenoid choice for current and former smokers.

6. Should I take lutein with food?

Yes. Lutein is fat-soluble and absorbs several-fold better with a meal containing at least about 5 grams of fat (olive oil, avocado, nuts, eggs, fatty fish). Oil-based softgels generally outperform tablets, powders or gummies.

7. Free-form lutein versus lutein esters — which is better?

Free-form has slightly higher per-milligram bioavailability and is the form used in AREDS2; esters can deliver comparable plasma exposure when taken with a fat-containing meal. Check the label for which is provided and whether the milligram figure refers to free lutein equivalent or to ester weight.

8. What foods are highest in lutein?

Raw kale (18–39 mg per 100 g), raw spinach (~12 mg per 100 g), watercress (~6 mg per 100 g) lead; egg yolks deliver 0.25–0.36 mg per yolk with unusually high bioavailability. Corn, red peppers and goji berries are notable sources of zeaxanthin specifically. The average American adult eats only 1–2 mg of lutein + zeaxanthin per day from food, well below the 12 mg combined dose used in AREDS2.

9. Can lutein replace sunscreen?

No. Oral antioxidants including lutein do not replace broad-spectrum topical sunscreen. Trials reporting improved "photo-protective activity" measure skin redness, hydration and similar parameters, not skin cancer prevention. SPF 30+ sunscreen, shade and protective clothing remain the dominant evidence-based measures against UV damage.

10. Is lutein safe in pregnancy?

Dietary lutein from leafy greens, eggs and corn is regarded as safe across the lifespan. Supplement-level doses have not been specifically evaluated in randomized trials in pregnant or breastfeeding women; food is the conservative, widely endorsed default during these life stages.

11. Can I take lutein with a β-carotene supplement?

When high doses are taken together, they compete for intestinal absorption — lutein bioavailability can be reduced by approximately 39–46% (Kostic et al., 1995, PMID 7661123). Space them across different meals, or choose a single lutein-zeaxanthin product.

12. What is meso-zeaxanthin and do I need to supplement it?

Meso-zeaxanthin is a stereoisomer of zeaxanthin (3R,3′S) that the body generates in the retina from dietary lutein via enzymatic isomerization. It is not an independently essential nutrient and is essentially absent from the ordinary diet. Some advanced macular formulas add it; the clinical evidence base for the supplemental form is more limited than for the lutein-zeaxanthin pair, and adequate dietary lutein is the most reliable way for the body to produce meso-zeaxanthin where needed.

← Back to Carotenoids cluster hub · All Ingredients